Adjuvant docetaxel for node-positive breast cancer

Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C. Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel

doi:10.1056/NEJMoa043681

Adjuvant docetaxel for node-positive breast cancer

Miguel Martin
, Tadeusz Pienkowski
, John Mackey
, Marek Pawlicki
, Jean Paul Guastalla
, Charles Weaver
, Eva Tomiak
, Taher Al-Tweigeri
, Linnea Chap
, Eva Juhos
, Raymond Guevin
, Anthony Howell
, Tommy Fornander
, John Hainsworth
, Robert Coleman
, Jeferson Vinholes
, Manuel Modiano
, Tamas Pinter
, Shou C. Tang
, Bruce Colwell

Catherine Prady, Louise Provencher, David Walde, Alvaro Rodriguez-Lescure, Judith Hugh, Camille Loret, Matthieu Rupin, Sandra Blitz, Philip Jacobs, Michael Murawsky, Alessandro Riva, Charles Vogel

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P

Original language	English
Pages (from-to)	2302-2313
Number of pages	11
Journal	New England Journal Of Medicine
Volume	352
Issue number	22
DOIs	https://doi.org/10.1056/NEJMoa043681
Publication status	Published - 2 Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adult
Aged
adverse effects: Antineoplastic Agents, Phytogenic
administration & dosage: Antineoplastic Combined Chemotherapy Protocols
drug therapy: Breast Neoplasms
Chemotherapy, Adjuvant
administration & dosage: Cyclophosphamide
Disease-Free Survival
administration & dosage: Doxorubicin
Female
administration & dosage: Fluorouracil
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Quality of Life
Research Support, Non-U.S. Gov't
Survival Analysis
adverse effects: Taxoids

Access to Document

10.1056/NEJMoa043681

Cite this

Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., Guevin, R., Howell, A., Fornander, T., Hainsworth, J., Coleman, R., Vinholes, J., Modiano, M., Pinter, T., Tang, S. C., ... Vogel, C. (2005). Adjuvant docetaxel for node-positive breast cancer. New England Journal Of Medicine, 352(22), 2302-2313. https://doi.org/10.1056/NEJMoa043681

@article{c0c53cf6d1974269b28861cf6f620764,

title = "Adjuvant docetaxel for node-positive breast cancer",

abstract = "BACKGROUND We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P",

keywords = "Adult, Aged, adverse effects: Antineoplastic Agents, Phytogenic, administration \& dosage: Antineoplastic Combined Chemotherapy Protocols, drug therapy: Breast Neoplasms, Chemotherapy, Adjuvant, administration \& dosage: Cyclophosphamide, Disease-Free Survival, administration \& dosage: Doxorubicin, Female, administration \& dosage: Fluorouracil, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Quality of Life, Research Support, Non-U.S. Gov't, Survival Analysis, adverse effects: Taxoids",

author = "Miguel Martin and Tadeusz Pienkowski and John Mackey and Marek Pawlicki and Guastalla, \{Jean Paul\} and Charles Weaver and Eva Tomiak and Taher Al-Tweigeri and Linnea Chap and Eva Juhos and Raymond Guevin and Anthony Howell and Tommy Fornander and John Hainsworth and Robert Coleman and Jeferson Vinholes and Manuel Modiano and Tamas Pinter and Tang, \{Shou C.\} and Bruce Colwell and Catherine Prady and Louise Provencher and David Walde and Alvaro Rodriguez-Lescure and Judith Hugh and Camille Loret and Matthieu Rupin and Sandra Blitz and Philip Jacobs and Michael Murawsky and Alessandro Riva and Charles Vogel",

year = "2005",

month = jun,

day = "2",

doi = "10.1056/NEJMoa043681",

language = "English",

volume = "352",

pages = "2302--2313",

journal = "New England Journal Of Medicine",

issn = "1533-4406",

publisher = "Massachussetts Medical Society",

number = "22",

}

Martin, M, Pienkowski, T, Mackey, J, Pawlicki, M, Guastalla, JP, Weaver, C, Tomiak, E, Al-Tweigeri, T, Chap, L, Juhos, E, Guevin, R, Howell, A, Fornander, T, Hainsworth, J, Coleman, R, Vinholes, J, Modiano, M, Pinter, T, Tang, SC, Colwell, B, Prady, C, Provencher, L, Walde, D, Rodriguez-Lescure, A, Hugh, J, Loret, C, Rupin, M, Blitz, S, Jacobs, P, Murawsky, M, Riva, A & Vogel, C 2005, 'Adjuvant docetaxel for node-positive breast cancer', New England Journal Of Medicine, vol. 352, no. 22, pp. 2302-2313. https://doi.org/10.1056/NEJMoa043681

TY - JOUR

T1 - Adjuvant docetaxel for node-positive breast cancer

AU - Martin, Miguel

AU - Pienkowski, Tadeusz

AU - Mackey, John

AU - Pawlicki, Marek

AU - Guastalla, Jean Paul

AU - Weaver, Charles

AU - Tomiak, Eva

AU - Al-Tweigeri, Taher

AU - Chap, Linnea

AU - Juhos, Eva

AU - Guevin, Raymond

AU - Howell, Anthony

AU - Fornander, Tommy

AU - Hainsworth, John

AU - Coleman, Robert

AU - Vinholes, Jeferson

AU - Modiano, Manuel

AU - Pinter, Tamas

AU - Tang, Shou C.

AU - Colwell, Bruce

AU - Prady, Catherine

AU - Provencher, Louise

AU - Walde, David

AU - Rodriguez-Lescure, Alvaro

AU - Hugh, Judith

AU - Loret, Camille

AU - Rupin, Matthieu

AU - Blitz, Sandra

AU - Jacobs, Philip

AU - Murawsky, Michael

AU - Riva, Alessandro

AU - Vogel, Charles

PY - 2005/6/2

Y1 - 2005/6/2

N2 - BACKGROUND We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P

AB - BACKGROUND We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P

KW - Adult

KW - Aged

KW - adverse effects: Antineoplastic Agents, Phytogenic

KW - administration & dosage: Antineoplastic Combined Chemotherapy Protocols

KW - drug therapy: Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - administration & dosage: Cyclophosphamide

KW - Disease-Free Survival

KW - administration & dosage: Doxorubicin

KW - Female

KW - administration & dosage: Fluorouracil

KW - Follow-Up Studies

KW - Humans

KW - Lymphatic Metastasis

KW - Middle Aged

KW - Quality of Life

KW - Research Support, Non-U.S. Gov't

KW - Survival Analysis

KW - adverse effects: Taxoids

U2 - 10.1056/NEJMoa043681

DO - 10.1056/NEJMoa043681

M3 - Article

SN - 1533-4406

VL - 352

SP - 2302

EP - 2313

JO - New England Journal Of Medicine

JF - New England Journal Of Medicine

IS - 22

ER -

Adjuvant docetaxel for node-positive breast cancer

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this